The Debt Recovery Tribunal (DRT) in Chennai cleared the decks for Orchid Pharma to transfer its pencillin and penems API business along with some facilities to the US-based Hospira over a $200 million deal which was announced in August, 2012.
The DRT 1, Chennai, vacated a stay on the Business Transfer Agreement (BTA) between the companies, which was issued almost an year ago in favour of one of ING Vysya Bank, a lender to Orchid Pharma.
Sources close to the development confirmed the order and said the tribunal had pronounced the order on Tuesday.
During the hearing, ING Vysya Bank has argued Orchid had to pay around Rs 44 crore to the bank given to the latter for the working capital, which the company had used for long-term purpose. The Bank said that its accounts should be settled before implementing any agreement.
The bank also said it had opposed the corporate debt restructuring (CDR) package, as it would not receive the actual amount in its implementation.
However, Orchid Pharma argued the CDR proposal was duly accepted by the CDR Empowered Group, and according to which, its creditors, around 22 banks, would be getting a portion of the money they had lent while all of them were sacrificing a part of it, as it is required for the company's revival and payment of debt.
Orchid had argued 22 banks were involved in the CDR and the creditors were sacrificing Rs 364 crore, mostly the interest on credit.
The proposed BTA, which is now a part of the CDR procedure, has been into litigation as some of the debtors and shareholders of the company.
Also, Orchid's dispute with its largest shareholder group, billionaire investor Cyrus Poonawalla and his firms, including the biotech firm Serum Institute, was recently heard in the Chennai Bench of Company Law Board (CLB).
Orchid Pharma also received a favourable order from the CLB, which refused to issue a stay on implementation of its corporate debt restructuring (CDR) programme.
The investor and his group, together holding around 14 per cent stake in the company, has alleged that certain acts of oppression and mismanagement in the affairs of Orchid Pharma.
They have also argued against the BTA, during the hearing in CLB.
The Business Transfer Agreement (BTA) between Orchid Chemicals and Pharmaceuticals Ltd and Hospira Health care (India) Pvt Ltd was signed in August, 2012, according to which Hospira agreed to buy the formers' facility in Aurangabad and affiliated facilities for over $200 million (which later increased to $218 million).
Orchid Pharma, which has been reeling under debt for the past few years, has around Rs 3,500 crore, according to recent reports.
According to earlier reports, the CDR scheme includes the sale of Orchid Pharma's penecillin and penems API business together with its manufacturing facilities at Aurangabad, Maharashtra and associated R&D facility at Sholinganallur, Chennai for a cash consideration of about Rs 1348 crore to Hospira. It also include repayment of a portion, Rs 681 crore, of the total debt to lenders out of the sale proceeds and restructuring of the balance debt of Rs 2866 crore. Around Rs 430 crore from the sale proceeds for meeting the working capital requirements of the company. The restructured debt together with funded loans would have to be repaid over a period of 8 years starting from April 2015 subject to regulatory approvals.
